WATCHMAN - Innovative stroke risk treatment
Huntington Hospital is the only facility in the San Gabriel Valley to offer
FDA-approved WATCHMAN™ Left Atrial Appendage Closure (LAAC) device
for patients with atrial fibrillation (AFib) as an alternative to the
lifelong use of warfarin or Novel Oral Anticoagulants (NOAC) for people
with AFib not caused by a heart valve problem (also known as non-valvular AFib).
Learn more about WATCHMAN at Huntington Hospital in our press release.
“The WATCHMAN device is a novel alternative for patients with non-valvular
AFib at risk for a stroke, especially those with a compelling reason not
to be on blood thinners,” said Alex Durairaj, MD, medical director
of cardiovascular services, Huntington Hospital. “We provide over
2,000 catheterizations and electrophysiology procedures, and 42,000 non-invasive
cardiac diagnostic procedures each year. I’m proud to now offer
this safe and effective procedure to our patients seeking stroke risk
Who is a candidate for WATCHMAN?
An estimated five million Americans are affected by AFib – an irregular
heartbeat that feels like a quivering heart. (1) People with AFib have
a five times greater risk of stroke (2) than those with normal heart rhythms.
The WATCHMAN device closes off an area of the heart called the left atrial
appendage (LAA) to keep harmful blood clots that can form in the LAA from
entering the blood stream and potentially causing a stroke. By closing
off the LAA, the risk of stroke may be reduced and, over time, patients
may be able to stop taking warfarin or NOAC.
How does WATCHMAN work?
The WATCHMAN device has been implanted in more than 50,000 patients worldwide
and is done via a one-time procedure. It’s a permanent device that
doesn’t have to be replaced and can’t be seen outside the
body. The procedure is done under general anesthesia and takes about an
hour. Patients commonly stay in the hospital overnight and leave the next day.
For more information on the WATCHMAN device, please visit: